Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update

Azitra, Inc. (NYSEAMERICAN:AZTR) was the target of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 154,671 shares, a decrease of 55.8% from the July 15th total of 349,646 shares. Based on an average daily trading volume, of 769,462 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.0% of the shares of the stock are short sold.

Azitra Stock Down 0.5%

NYSEAMERICAN AZTR traded down $0.00 during trading hours on Friday, hitting $0.14. 1,041,981 shares of the company’s stock traded hands, compared to its average volume of 1,476,759. Azitra has a 52-week low of $0.10 and a 52-week high of $1.40. The firm’s 50-day moving average is $0.16 and its 200-day moving average is $0.19.

Azitra (NYSEAMERICAN:AZTR) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). As a group, sell-side analysts predict that Azitra will post -0.25 EPS for the current fiscal year.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.